Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: GSK stock price vs GVA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GVA's multiple
Needs GVA P/E.
Implied fair value · at GSK's multiple
Needs GSK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · GVA FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 75% equity / 25% debt · EV / Revenue 1.43x · EV / EBITDA 20.04x
GSK carries the larger enterprise value at $163.76B against $6.34B; GVA trades on the lower EV / Revenue multiple (1.43x vs 3.71x); GSK on the lower EV / EBITDA (19.25x vs 20.04x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
GRANITE CONSTRUCTION INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
1.45x
Net debt / EBITDA
Leverage against operating earnings
6.59x
3.53x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$600.24M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
AECOM
GSK vs ACM
STERLING INFRASTRUCTURE, INC.
GSK vs STRL
MASTEC INC
GSK vs MTZ
JACOBS SOLUTIONS INC.
GSK vs J
EMCOR Group, Inc.
GSK vs EME
QUANTA SERVICES, INC.
GSK vs PWR
$1.72B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
